DENTALMONITORING
14.6.2024 19:35:30 CEST | Business Wire | Press release
DentalMonitoring is proud to announce that the DentalMonitoring Software is now certified under the European Union Medical Device Regulation 2017/745 (EU MDR) and fulfills the requirements for CE marking as a class IIa medical device. European Medical Device Regulation 2017/745 (EU MDR) replaces the previous Medical Device Directive 93/42/EEC (MDD). EU MDR sets more rigorous requirements for clinical evaluation, risk management, post-market surveillance, and data collection on medical devices.(1) This landmark achievement underscores DentalMonitoring's commitment to advancing dental care through cutting-edge technology and rigorous regulatory compliance. Achieving this certification four years ahead of the deadline demonstrates DentalMonitoring's commitment to positioning itself as an innovative, serious, efficient, and safe player in the medical field.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240614842101/en/
DentalMonitoring Sets New Standard in Orthodontic Remote Monitoring with EU-MDR Certification (Graphic: Business Wire)
DentalMonitoring is a medical device software using image processing algorithms to analyze high-quality intraoral scans taken by patients using the DM App, a smartphone, and proprietary hardware. The software allows healthcare professionals to remotely monitor dental treatments, orthodontic treatments, oral health, and treatment progress. The medical device software aids clinicians in diagnosis and treatment planning through weekly clinical updates.
With DentalMonitoring, clinicians enjoy an elevated level of insight into treatment progress while patients enjoy increased convenience. Automated notifications and in-app communication with practice staff increase patient accountability and enhance communication between patients and healthcare providers. This level of connection promotes patient compliance with orthodontic treatment requirements.
Philippe Salah, CEO and co-founder of DentalMonitoring, said, “I’m incredibly proud that DentalMonitoring has achieved EU MDR certification along with US/FDA DeNovo 510k clearance. These achievements celebrate our relentless pursuit of innovation and excellence in oral care. Our AI-powered solutions are now recognized at the highest regulatory levels, enabling us to expand our reach and impact more lives with advanced dental technology.”
“The requirements of EU MDR are much more rigorous, sometimes compelling medical device manufacturers to rethink their European commercial strategy. We are very pleased to have successfully met these requirements four years before the deadline set by the European Union. EU MDR Certification is a significant milestone that underscores DentalMonitoring's commitment to quality, efficiency and patient safety,” said Arnaud Berthier, Director of Regulatory, Quality and Clinical Affairs at DentalMonitoring.
About DentalMonitoring:
DentalMonitoring is transforming orthodontic care globally through our advanced AI-driven platform. Our mission is to empower orthodontic practitioners with precise, real-time treatment monitoring and decision-making tools. By enhancing the connection between clinicians and patients, we make it possible to optimize treatment outcomes and ensure high-quality, efficient, and personalized orthodontic experiences. Visit www.DentalMonitoring.com and follow DentalMonitoring on LinkedIn.
(1) |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240614842101/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis Convenes Global Supply Chain Leaders at Kinexions North America to Advance Agentic AI and Decision Orchestration28.5.2026 13:00:00 CEST | Press release
Annual conference brings customers, partners, and industry leaders together to explore how enterprises are turning decisions into coordinated action Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, is set to host Kinexions North America kicking off next week from June 1-3 at The Cosmopolitan of Las Vegas. The company’s flagship conference will bring together global supply chain, business and technology leaders for three days of product innovation, customer insights, and peer networking as Kinaxis continues to advance its focus on AI-driven decision making across the supply chain industry. This year’s event will spotlight how organizations are applying agentic AI and orchestration, moving beyond insight to execution, and increasingly from decisions to coordinated action. Speakers from global organizations including Merck, Bristol Myers Squibb, Unilever, British American Tobacco, Qualcomm, ExxonMobil, The Hershey Company, Scotts Miracle-Gro, and
Amadeus Redefines Travel Advertising to Help Brands Capture Demand Earlier28.5.2026 13:00:00 CEST | Press release
Developed in collaboration with Accenture, the AI-powered platform helps travel brands make smarter advertising decisions earlier and drive profitable demand through greater control, transparency, efficiency and performance. Amadeus today introduced the Amadeus Travel Advertising Platform at its Advertising Summit in Nice, France. Leveraging Accenture’s agentic framework for campaign execution, the platform outlines a new approach designed to help travel companies make faster, smarter advertising decisions based on where demand is forming — not just where it has already converted. Travel advertising has become increasingly complex, fragmented across channels and often driven by historical performance signals that arrive too late to capture emerging demand. As travelers plan trips across AI chatbots, search, social, metasearch, content platforms and OTAs long before booking, travel brands face rising acquisition costs and growing pressure to prove return on investment. The Amadeus Trave
Compass Pathways Elects Kathleen Tregoning to Board of Directors28.5.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the election of Kathleen Tregoning to its Board of Directors at the annual general meeting of shareholders. Ms. Tregoning is expected to serve on the Compensation and Leadership Development Committee and the Nominating and Corporate Governance Committee. She brings extensive experience guiding biopharmaceutical companies through periods of growth and transformation, with expertise spanning corporate strategy, external affairs, public policy and patient access. “With two successful Phase 3 trials meeting the primary endpoint, a transformative clinical profile for COMP360, and a rolling NDA submission and review now underway, Compass is strongly positioned to make our goal of securing an FDA approval a reality. Compass is entering a stage where experience in external engagement, public policy, and patient access matters more
Alzprotect Announces FDA Clearance of IND for AZP2006 (Ezeprogind®) in Progressive Supranuclear Palsy (PSP)28.5.2026 12:28:00 CEST | Press release
IND enables initiation of U.S. clinical development in PSP Alzprotect today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for AZP2006 (Ezeprogind®) for the treatment of Progressive Supranuclear Palsy (PSP). FDA clearance permits the Company to begin clinical development of AZP2006 in the United States. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526387210/en/ “FDA IND clearance is a pivotal step in our PSP program,” said Philippe Verwaerde, PhD, President & Chief science Officer. “We can now expand our clinical efforts in the U.S. to evaluate AZP2006’s potential to address PSP, a severe neurodegenerative disease with no approved disease-modifying therapies.” Dr. Artin Karapet, Chief Medical Officer, commented: “The FDA’s clearance of our IND for AZP2006 is a pivotal milestone, aligning U.S. and European regulatory pathways and enabling th
LMR by IFF Inaugurates New Experimental Field in Grasse28.5.2026 11:00:00 CEST | Press release
Furthering IFF’s leadership in natural ingredients for perfumery. LMR Naturals by IFF—a global leader in natural ingredients for perfumery, cosmetics and flavors—today inaugurated its new experimental field, Domaine des Naturels LMR. The field is dedicated to advancing research in natural ingredients, preserving Grasse’s agricultural heritage and expanding education in naturals. The inauguration, attended by Grasse Mayor Jérôme Viaud, a long-standing supporter of the perfume industry, underscores IFF and LMR’s ongoing commitment to the region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260527694524/en/ At Domaine des Naturels LMR, R&D experts research new natural species, variety breeding, cultivation methods and production techniques. “This inauguration reflects over two decades of continuous investment in Grasse and in naturals,” said Ana Paula Mendonça, president, Scent, IFF. “With Domaine des Naturels LMR, we are bri
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom